Scarica l'app Stockscreener
5.0026
2.02%
0.1026
Precedente Chiudi:
$4.90
Aprire:
$4.94
Volume 24 ore:
650.93K
Relative Volume:
0.49
Capitalizzazione di mercato:
$324.42M
Reddito:
$202.09M
Utile/perdita netta:
$-61.69M
Rapporto P/E:
-4.632
EPS:
-1.08
Flusso di cassa netto:
$-35.64M
1 W Prestazione:
-0.02%
1M Prestazione:
-30.47%
6M Prestazione:
-47.76%
1 anno Prestazione:
-64.62%
Intervallo 1D:
$4.88
$5.10
Intervallo di 1 settimana:
$4.81
$5.24
Portata 52W:
$4.7401
$17.12
Evolus Inc Stock (EOLS) Company Profile
Nome
Evolus Inc
Settore
Telefono
(949) 284-4555
Indirizzo
520 NEWPORT CENTER DRIVE, NEWPORT BEACH
Confronta EOLS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
EOLS
Evolus Inc
|
5.005 | 317.62M | 202.09M | -61.69M | -35.64M | -1.08 |
|
ZTS
Zoetis Inc
|
124.03 | 55.12B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.97 | 50.80B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
10.27 | 45.60B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.64 | 36.04B | 16.88B | 666.71M | 251.19M | 0.6132 |
|
UTHR
United Therapeutics Corp
|
470.62 | 20.23B | 3.08B | 1.24B | 1.07B | 25.61 |
Evolus Inc Stock (EOLS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-08-06 | Downgrade | Needham | Buy → Hold |
| 2025-04-17 | Iniziato | BTIG Research | Buy |
| 2024-01-29 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2022-06-23 | Iniziato | Needham | Buy |
| 2022-05-12 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2022-01-20 | Aggiornamento | Truist | Hold → Buy |
| 2021-05-06 | Aggiornamento | Mizuho | Neutral → Buy |
| 2021-04-08 | Reiterato | H.C. Wainwright | Buy |
| 2021-02-24 | Downgrade | Truist | Buy → Hold |
| 2020-07-07 | Downgrade | Mizuho | Buy → Neutral |
| 2020-02-06 | Ripresa | Mizuho | Buy |
| 2019-11-26 | Iniziato | SVB Leerink | Outperform |
| 2019-09-05 | Ripresa | Mizuho | Buy |
| 2019-06-28 | Iniziato | Wells Fargo | Market Perform |
| 2019-06-11 | Iniziato | Barclays | Underweight |
| 2019-03-20 | Iniziato | SunTrust | Buy |
| 2019-02-14 | Iniziato | H.C. Wainwright | Buy |
| 2019-01-29 | Iniziato | Stifel | Buy |
Mostra tutto
Evolus Inc Borsa (EOLS) Ultime notizie
Evolus (NASDAQ:EOLS) Given New $13.00 Price Target at BTIG Research - MarketBeat
EOLS: BTIG Lowers Price Target While Maintaining Buy Rating | EO - GuruFocus
Understanding Momentum Shifts in (EOLS) - Stock Traders Daily
BTIG lowers Evolus stock price target to $13 on aesthetic market decline By Investing.com - Investing.com South Africa
BTIG lowers Evolus stock price target to $13 on aesthetic market decline - Investing.com
Evolus projects robust 2025 growth with upcoming product launches - MSN
Panic Selling: Should you avoid Evolus Inc stock right nowEarnings Performance Report & Capital Efficient Trade Techniques - baoquankhu1.vn
Lacklustre Performance Is Driving Evolus, Inc.'s (NASDAQ:EOLS) 30% Price Drop - 富途牛牛
VIX Spike: Is Evolus Inc undervalued by DCF analysis2025 Market WrapUp & Safe Entry Trade Reports - baoquankhu1.vn
Stifel Analyst Lowers Price Target on Evolus (EOLS) to $17.00 | - GuruFocus
Stifel lowers Evolus stock price target to $17 on tempered growth outlook - Investing.com Australia
Stifel lowers Evolus stock price target to $17 on tempered growth outlook By Investing.com - Investing.com South Africa
Evolus, Inc. (NASDAQ:EOLS) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Avoiding Lag: Real-Time Signals in (EOLS) Movement - Stock Traders Daily
Evolus reports 15% Q4 growth, projects 2026 profitability By Investing.com - Investing.com Nigeria
Evolus sees FY26 revenue $327M-$337M, consensus $351.66M - TipRanks
Evolus sees Q4 revenue $88.6M-$90.6M, consensus $90.91M - TipRanks
Evolus, Inc. (EOLS) Stock Analysis: Unpacking a 222% Potential Upside in the Aesthetic Market - DirectorsTalk Interviews
EOLS: HC Wainwright & Co. Reiterates Buy Rating with $20 Price T - GuruFocus
Evolus' (EOLS) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat
Evolus (EOLS) Projects Strong Revenue Growth Through 2028 - GuruFocus
EOLS Projects Strong Revenue Growth with Key Product Line - GuruFocus
Evolus (EOLS) Achieves Sixth Year of Double-Digit Growth in 2025 - GuruFocus
EOLS Projects Optimistic Growth with Strategic Market Expansion - GuruFocus
Evolus outlook FY sales USD 327-337 million - marketscreener.com
Evolus reports 15% Q4 growth, projects 2026 profitability - Investing.com
Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2025 Net Revenue - Business Wire
How Evolus Inc. stock valuations compare to rivalsMarket Growth Review & Stock Timing and Entry Methods - Улправда
Does Evolus Inc. stock trade at a discount to peersChart Signals & Reliable Breakout Forecasts - Улправда
Why Evolus Inc. stock is favored by top institutions2025 Performance Recap & Expert Curated Trade Setup Alerts - Улправда
Can Evolus Inc. stock deliver strong Q4 earningsSwing Trading Ideas & Small Budget Portfolio Growth - Улправда
Insider Sellers Might Regret Selling Evolus Shares at a Lower Price Than Current Market Value - simplywall.st
Mizuho cuts Evolus (EOLS) estimates for Jeuveau/Evolysse on waning consumer sentiment and inflationary pressure on elective aesthetics - MSN
Will Evolus Inc. (EVL) stock benefit from sector leadershipRisk Mitigation Techniques & Low Entry Cost Investments - ulpravda.ru
Analysts Offer Insights on Healthcare Companies: Arrowhead Pharmaceuticals (ARWR) and Evolus (EOLS) - The Globe and Mail
Discipline and Rules-Based Execution in EOLS Response - Stock Traders Daily
Avelar Rui, Evolus officer, sells $16k in EOLS stock By Investing.com - Investing.com India
Evolus CEO Moatazedi sells $75k in shares By Investing.com - Investing.com Australia
Evolus CEO Moatazedi sells $75k in shares - Investing.com
Avelar Rui, Evolus officer, sells $16k in EOLS stock - Investing.com
Insider Selling: Evolus (NASDAQ:EOLS) Insider Sells 10,539 Shares of Stock - MarketBeat
Rui Avelar Sells 2,261 Shares of Evolus (NASDAQ:EOLS) Stock - MarketBeat
ANI Stock Is Up 49% This Past Year, Revenue Is Surging, and One Fund Still Walked Away - The Motley Fool
Evolus, Inc. $EOLS Shares Acquired by Rice Hall James & Associates LLC - MarketBeat
Big Picture: Does Evolus Inc stock trade at a discount to peersPortfolio Update Summary & AI Powered Buy and Sell Recommendations - moha.gov.vn
Evolus' (EOLS) "Hold" Rating Reaffirmed at Needham & Company LLC - MarketBeat
Needham Reiterates Evolus (EOLS) Hold Recommendation - Nasdaq
Needham Reiterates Hold Rating for Evolus (EOLS) | EOLS Stock Ne - GuruFocus
Net current asset value per share of Evolus, Inc. – BER:EVL - TradingView — Track All Markets
Trading the Move, Not the Narrative: (EOLS) Edition - Stock Traders Daily
EV Market: Why Evolus Inc. stock is a must watch in 2025Earnings Growth Summary & Consistent Return Investment Signals - Улправда
Evolus Inc Azioni (EOLS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Evolus Inc Azioni (EOLS) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Avelar Rui | See Remarks |
Dec 22 '25 |
Sale |
7.15 |
2,261 |
16,168 |
356,821 |
| Yamagishi-Dressler Tomoko | Chief Marketing Officer |
Aug 22 '25 |
Sale |
7.51 |
5,722 |
42,972 |
89,949 |
| Stewart Brady | Director |
Aug 15 '25 |
Buy |
6.82 |
30,000 |
204,486 |
88,629 |
| MOATAZEDI DAVID | See Remarks |
Jun 13 '25 |
Sale |
10.05 |
111,323 |
1,119,141 |
381,509 |
| MOATAZEDI DAVID | See Remarks |
Jun 16 '25 |
Sale |
9.89 |
16,582 |
164,054 |
364,927 |
3.40%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):